N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
• 化学式: C₂₃H₂₉FN₄O₃
• 分子量: 428.5
• InChiKey: OCZYWUNAORCGGL-ZDLGFXPLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  97.5
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• Treatment of acute myeloid leukemia with indolinone compounds
  申请人：SUGEN, Inc.

  公开号：US20030130280A1

  公开（公告）日：2003-07-10

  A method of treating acute myeloid leukemia in patient positive for FLT-3-ITD is described. The treatment is accomplished by administration of a compound of Formula I or II as defined herein.

  描述了一种治疗FLT-3-ITD阳性患者急性髓系白血病的方法。该治疗通过给予本文中定义的I或II式化合物来实现。
• Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
  申请人：SUGEN, Inc.

  公开号：US20040152759A1

  公开（公告）日：2004-08-05

  The invention relates to a method of treating cancer by administering a combination of an indolinone compound with another chemotherapeutic agent. The combination of an indolinone compound of Formula I: 1 with another chemotherapeutic agent provides an enhanced effect in treating cancer patients.

  本发明涉及一种治疗癌症的方法，通过给予一种吲哚酮化合物和另一种化疗药物的组合物。一种式子为I：1的吲哚酮化合物与另一种化疗药物的组合物在治疗癌症患者方面提供了增强效果。
• 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：Guan Huiping

  公开号：US20080045709A1

  公开（公告）日：2008-02-21

  The present invention provides a method to make a pyrrole substituted 2-indolinone compound of the formula

  本发明提供了一种制备式中的吡咯取代的2-吲哚酮化合物的方法。
• 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone der derivatives as protein kinase inhibitors
  申请人：Guan Huiping

  公开号：US20070027149A1

  公开（公告）日：2007-02-01

  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯取代的2-吲哚酮化合物及其药学上可接受的盐，这些化合物调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面有用。
• US7179910B2
  申请人：——

  公开号：US7179910B2

  公开（公告）日：2007-02-20